Glucose Fresenius (Glucose Monohydrate)

Glucose Fresenius is an intravenous solution for injection that contains the active ingredient glucose monohydrate. The product’s strength is not specified in the available data, and it is supplied as a sterile solution intended for parenteral administration. As an excipient and solvent, it provides carbohydrate energy and fluid volume when infused. It is marketed within the European Union and is classified under ATC code B05BA01 for parenteral nutrition and fluid replacement.

Glucose Fresenius is used in clinical settings to address conditions that require rapid carbohydrate supplementation or fluid replacement.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid replacement in patients with dehydration or electrolyte imbalance. - Support during surgical procedures to maintain blood glucose levels. - Adjunct therapy in critical care to provide an energy substrate.

Intravenous administration of glucose solutions may be associated with a range of adverse effects, most of which are related to the osmolarity and rapid infusion of carbohydrate.

Common: - Transient hyperglycemia. - Local irritation or pain at the infusion site. - Nausea or mild vomiting. - Electrolyte shifts such as mild hyponatremia.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload and pulmonary edema. - Hyperosmolar hyperglycemic state (HHS) in susceptible patients. - Allergic or anaphylactic reaction to the solution.

Before administering Glucose Fresenius, clinicians should evaluate patient-specific factors and monitor for potential complications.

- Assess baseline blood glucose and adjust infusion rate accordingly. - Use caution in patients with renal or cardiac failure due to risk of fluid overload. - Avoid rapid infusion in neonates and infants to prevent hyperglycemia. - Monitor electrolytes, especially sodium and potassium, during therapy. - Ensure sterility of the solution and proper storage conditions. - Consider contraindications such as known hypersensitivity to glucose solutions.

Glucose Fresenius may interact with other medications or clinical conditions, influencing its safety and efficacy.

Avoid: - Co-administration with insulin bolus doses without adjusting the insulin regimen. - Simultaneous infusion of high‑osmolarity solutions that may exacerbate hyperglycemia. - Use in patients receiving diuretics that predispose to electrolyte disturbances without monitoring.

Use with caution: - Concurrent use of beta‑blockers, which can mask signs of hypoglycemia. - Administration alongside corticosteroids that increase glucose production. - Patients on total parenteral nutrition formulas; adjust total carbohydrate load.